Hua Medicine
HKEX:2552
Hua Medicine
Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.
Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.